SLC4A2

Across TCGA pan-cancer cohorts, SLC4A2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC4A2 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC4A2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SLC4A2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SLC4A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.648	0.258	<.001	36	view →
LUAD	OS	Quartile	III,IV	0.248	0.794	.005	12	view →
CCRCC	DFS	Tertile	III,IV	0.410	0.725	.013	6	view →
UCEC	DFS	Tertile	All	0.921	1.000	.032	4	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC4A2–PDAC (OS)

Open the PDAC breakdown →